[go: up one dir, main page]

MX2016002051A - Metodos y kits para la subtipificacion molecular de tumores. - Google Patents

Metodos y kits para la subtipificacion molecular de tumores.

Info

Publication number
MX2016002051A
MX2016002051A MX2016002051A MX2016002051A MX2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A
Authority
MX
Mexico
Prior art keywords
kits
tumors
methods
molecular subtyping
cancer patient
Prior art date
Application number
MX2016002051A
Other languages
English (en)
Inventor
Wirtz Ralph
KNEIP Christoph
Original Assignee
Biontech Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Diagnostics Gmbh filed Critical Biontech Diagnostics Gmbh
Publication of MX2016002051A publication Critical patent/MX2016002051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona a un método in vitro de identificación del subtipo molecular de un tumor en un paciente con cáncer y a un método de estratificación de un paciente con cáncer para el tratamiento de tumor. La presente invención se relaciona además a kits que son útiles para la identificación de un subtipo molecular de un tumor en un paciente con cáncer.
MX2016002051A 2013-08-19 2014-08-19 Metodos y kits para la subtipificacion molecular de tumores. MX2016002051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2013002487 2013-08-19
PCT/EP2014/067675 WO2015024942A1 (en) 2013-08-19 2014-08-19 Methods and kits for the molecular subtyping of tumors

Publications (1)

Publication Number Publication Date
MX2016002051A true MX2016002051A (es) 2016-08-17

Family

ID=51399644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002051A MX2016002051A (es) 2013-08-19 2014-08-19 Metodos y kits para la subtipificacion molecular de tumores.

Country Status (17)

Country Link
US (2) US10808283B2 (es)
JP (1) JP6691864B2 (es)
KR (1) KR102241973B1 (es)
CN (3) CN119242793A (es)
AU (1) AU2014310606B2 (es)
CA (1) CA2921183A1 (es)
DK (1) DK2959021T3 (es)
ES (2) ES2951470T3 (es)
HK (1) HK1218313A1 (es)
HU (1) HUE040066T2 (es)
IL (1) IL243430B (es)
MX (1) MX2016002051A (es)
NZ (1) NZ716862A (es)
PT (1) PT2959021T (es)
RU (1) RU2690241C2 (es)
SG (1) SG11201601060RA (es)
WO (1) WO2015024942A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6691864B2 (ja) 2013-08-19 2020-05-13 ビオンテック・ダイアグノスティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢｉｏＮＴｅｃｈ Ｄｉａｇｎｏｓｔｉｃｓ ＧｍｂＨ 腫瘍の分子サブタイプ化のための方法およびキット
CN114717312B (zh) * 2015-02-17 2024-04-26 浙江数问生物技术有限公司 用于膀胱癌分子亚型分型的方法和试剂盒
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
EP3496774A1 (en) * 2016-08-15 2019-06-19 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CN106676000A (zh) * 2016-12-30 2017-05-17 上海星耀医学科技发展有限公司 多腔室基因分析反应装置
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CN109385473A (zh) * 2017-08-08 2019-02-26 安徽普元生物科技股份有限公司 HER2基因mRNA核酸检测试剂盒（PCR-荧光探针法）
CN111433176B (zh) 2017-10-04 2023-08-29 巴特尔纪念研究院 用于选择性表征异生物质代谢中涉及的酶的探针以及制造和使用该探针的方法
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CN113383091B (zh) 2018-09-27 2025-03-04 百欧恩泰诊断有限责任公司 乳腺癌的预测和预后方法
CN109207596A (zh) * 2018-10-07 2019-01-15 浙江数问生物技术有限公司 一种MKi67基因表达检测试剂盒及其检测方法
CN113302313A (zh) * 2018-11-05 2021-08-24 拜恩科技诊断有限责任公司 乳腺癌的预测方法
CN109913551A (zh) * 2019-03-26 2019-06-21 深圳大学 乳腺癌分型的核酸组合物、乳腺癌分型试剂盒及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541141B2 (en) * 1997-02-27 2009-06-02 Wisconsin Alumni Research Foundation Method of using estrogen-related receptor alpha (ERRα) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRα as a therapeutic target for the treatment of breast cancer
CN101061480A (zh) * 2004-09-22 2007-10-24 三路影像公司 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品
JP4896994B2 (ja) * 2006-02-09 2012-03-14 ユニバーシティー オブ サウス フロリダ Ｂｃｌ−２レベルの上昇による癌の検出
CA2725760C (en) 2008-05-30 2019-07-02 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
CN102337327A (zh) * 2010-07-21 2012-02-01 其昌達生物高科技(上海)有限公司 乳腺癌预后28基因阵列检测系统
CN102586410A (zh) * 2011-01-18 2012-07-18 苏州科贝生物技术有限公司 一种定量评估乳腺癌远期复发风险的试剂盒
AU2012345789B2 (en) * 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
EP3415639B8 (en) 2013-08-19 2023-07-12 Shuwen Biotech Co., Ltd. Methods and kits for the molecular subtyping of tumors
JP6691864B2 (ja) 2013-08-19 2020-05-13 ビオンテック・ダイアグノスティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢｉｏＮＴｅｃｈ Ｄｉａｇｎｏｓｔｉｃｓ ＧｍｂＨ 腫瘍の分子サブタイプ化のための方法およびキット

Also Published As

Publication number Publication date
CN105473735A (zh) 2016-04-06
ES2685580T3 (es) 2018-10-10
AU2014310606A1 (en) 2016-03-03
IL243430A0 (en) 2016-03-31
IL243430B (en) 2019-11-28
HUE040066T2 (hu) 2019-02-28
ES2951470T3 (es) 2023-10-23
WO2015024942A1 (en) 2015-02-26
JP2016527910A (ja) 2016-09-15
RU2016109976A (ru) 2017-09-28
CN110468205A (zh) 2019-11-19
RU2690241C2 (ru) 2019-05-31
US20200340065A1 (en) 2020-10-29
AU2014310606B2 (en) 2020-03-05
US10808283B2 (en) 2020-10-20
PT2959021T (pt) 2018-10-10
NZ716862A (en) 2022-05-27
KR102241973B1 (ko) 2021-04-19
JP6691864B2 (ja) 2020-05-13
DK2959021T3 (en) 2018-09-10
CA2921183A1 (en) 2015-02-26
CN119242793A (zh) 2025-01-03
HK1218313A1 (zh) 2017-02-10
SG11201601060RA (en) 2016-03-30
KR20160044033A (ko) 2016-04-22
US20160201137A1 (en) 2016-07-14
RU2016109976A3 (es) 2018-04-25

Similar Documents

Publication Publication Date Title
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
TN2015000396A1 (en) Antibody drug conjugates
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
GEP201706612B (en) Methods for the treatment of breast cancer
MX2023011187A (es) Metodos para tratar el cancer de prostata.
NZ723884A (en) Methods of treating alzheimer’s disease
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2015013021A (es) 5-bromo-indirrubinas.
PL2959021T3 (pl) Sposoby i zestawy do podtypowania molekularnego guzów
PH12016502298A1 (en) Vegfr2/ang2 compounds
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201990411A1 (ru) Способы лечения рака предстательной железы
EA201800552A1 (ru) Способ и комбинация для лечения солидной опухоли и набор, содержащий комбинацию